FDA approves drug to treat some obese, overweight adults

Some people who suffer from chronic weight issues may soon get some help from a pill.　

The U.S. Food and Drug Administration Wednesday approved Belviq, or lorcaserin hydrochloride, to be combined with a reduced-calorie diet and exercise, for treatment of chronic weight problems.

Specifically, the FDA says, it is approved for overweight or obese adults who have one or more medical conditions due to their weight, such as high blood pressure, type 2 diabetes or high cholesterol.

The FDA says the drug works by activating a receptor in the brain that helps a person to eat less and still feel full.

In trials, 47% of patients without type 2 diabetes lost at least 5% of their body weight. By comparison, 23% of patients treated with placebo lost at least 5% of their weight. In people with type 2 diabetes, 38% of patients on Belviq lost at least 5% of their body weight compared to 16% on placebo, according to the FDA.

"The results overall are quite modest," said Dr. Melina Jampolis, a physician nutrition specialist and CNN's diet and fitness expert. "But most experts agree that even a 5% weight loss has significant implications in terms of reducing the risk of obesity associated diseases including heart disease and diabetes."

The FDA says the manufacturer of Belviq, Arena Pharmaceuticals, will be required to conduct six postmarketing studies, including a long term cardiovascular trial to assess the risk of heart attack and stroke.

The most common side effects of Belviq in non-diabetic patients include headache, dizziness and fatigue; and in diabetic patients low blood sugar and pain, according to the FDA.